Seeking Alpha
10 Oct 2026, 10:33 UTC · 1h ago
Krystal Biotech: My Analysis Suggests Stock Has Not Yet Reached Peak Value
Impact · against what's priced in
The article provides a positive outlook for Krystal Biotech based on current fundamentals, but it fails to present new catalysts. Most of the reported metrics—including Vyjuvek's revenue run rate, cash position, and margins—are already reflected in the current valuation.
- KRYS+0.10
No priced-in read yet
- In context
While the Q2 revenue of $119.2m and $1.1bn cash position are strong, the current 12x forward P/E suggests the market has already largely accounted for the company's robust profitability and current growth trajectory.
Read from the article alone
Top 2 movers · tap to explore
